Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01857206 · ClinicalTrials.gov registry record · Phase 3
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,055
- Enrollment target
NCT01857206 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 2,055 participants.
The verdict
NCT01857206, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,055 participants
- Enrollment target
Study Summary
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
Interventions
- BIOLOGICAL Mammalian cell based flu vaccine
- BIOLOGICAL Egg based flu vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,055 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01857206
The ClinicalTrials.gov registry entry for NCT01857206 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,055 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mammalian cell based flu vaccine is the first listed.
NCT01857206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01857206 about?
NCT01857206 is a clinical study titled "Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age". Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
What is the current status of trial NCT01857206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,055 participants. The study started on 2013-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01857206?
The interventions under investigation include: Mammalian cell based flu vaccine (BIOLOGICAL), Egg based flu vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01857206?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.